



Name	: Mrs.REKHA GOYAL	Centre Details	:MALVIN DIAGNOSTICS
Age	: 37 Yrs Sex: Female	Accession.ID	:SDL2411150041
Collection Date	: 15/Nov/2024 12:51PM	Referred By	:DR GYNAE UNIT
Received Date	: 16/Nov/2024 09:07AM	Report Date	:18/Nov/2024 01:30PM
Registration Date	: 15/Nov/2024	Ref.No/TRF.No	: /

**DEPARTMENT OF CYTOLOGY**

**Conventional PAP Smear**  
Smear

**SPECIMEN DETAILS :**

**LAB. NO. : C/6335/24**

Conventional PAP smear  
One unstained smear.

**CLINICAL DETAILS:**

Cervix healthy.

**REPORTING MODE :**

By Bethesda System 2014

**ADEQUACY:**

Satisfactory for evaluation.  
Endocervical/transformation zone component absent.

**MICROSCOPY :**

Smear shows many intermediate cells, superficial squamous cells and moderate number of neutrophils.

**IMPRESSION :**

**Negative for any intraepithelial lesion or malignancy.**

Comment :

Retrospective case-control studies have failed to show an association between false-negative interpretations of specimens and lack of Endocervical cells (1,2). A recent Canadian review concluded that women should not be scheduled for early repeat testing because of lack of transformation zone sampling unless an abnormality was suspected (3,4).

1. Mitchell H, Medley G. Differences between Papanicolaou smears with correct and incorrect diagnoses. *Cytopathology*. 1995;6:368-75.
2. O'Sullivan JP, A'Hern RP, Chapman PA, Jenkins L, Smith R, al-Nafussi A, et al. A case-control study of true-positive versus false-negative cervical smears in women with cervical intraepithelial neoplasia (CIN) III. *Cytopathology*.1998;9:155-61.
3. Elumir-Tanner L. Doraty M. Management of Papanicolaou test results that lack endocervical cells. *Can Med Assoc J*. 2011;183:563-8.
4. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. *J. Low Genit Tract Dis*. 2013;17:S1-27.

**DISCLAIMER**

Gynaecological cytology is a screening test that aids in the detection of cervical cancer and cancer precursors. Both false positive and false negative results can occur. The test should be used at regular intervals, and positive results should be confirmed before definitive therapy.



Dr. Archana Sharma  
MBBS, MD, PDCC Liver Pathology  
Consultant Surgical Pathology  
DINC RG- No.64610



Name	: Mrs.REKHA GOYAL	Centre Details	:MALVIN DIAGNOSTICS
Age	: 37 Yrs Sex: Female	Accession.ID	:SDL2411150041
Collection Date	: 15/Nov/2024 12:51PM	Referred By	:DR GYNAE UNIT
Received Date	: 16/Nov/2024 09:07AM	Report Date	:18/Nov/2024 01:30PM
Registration Date	: 15/Nov/2024	Ref.No/TRF.No	: /

**DEPARTMENT OF CYTOLOGY**

**\*\*\* End Of Report \*\*\***

Disclaimer: All Results released pertain to the specimen submitted to the lab

1. Test results are dependent on the quality of the sample received by the lab
2. Tests are performed as per schedule given in the test listing and in any unforeseen circumstances, report delivery may be delayed
3. Test results may show interlaboratory variations
4. All dispute and claims are subjected to local jurisdiction only. Clinical correlation advised.
5. Test results are not valid for medico legal purposes
6. For all queries, feedbacks, suggestions, and complaints, please contact customer care support +0124 665 0000



Dr. Archana Sharma  
MBBS, MD, PDCC Liver Pathology  
Consultant Surgical Pathology  
DMC RG- No.64610





Name: Mrs. Rekha Gargal Age: 37y Sex: F  
 Dept: \_\_\_\_\_ Ref by: \_\_\_\_\_ Date: 15/11/24  
 M.R. No: \_\_\_\_\_ H/O: Dr. Alamy V.N.

**Deptt. of General & Laparoscopic Surgery**

**Dr. Vinay Sabharwal**

M.B.B.S., M.S. FCS  
 Hon. Surgeon to Fort. President of India  
 Sir Ganga Ram Hospital  
 Sr. Member - Association of Surgeons of India  
 Indian Association of Gyna. & Endo. Surgeons  
 Indian Herma Society  
 Area Supt. of Mr. Assoc. Surgeons of India  
 E-mail: [vinay@jmh.in](mailto:vinay@jmh.in)  
 Website: [www.drvinay@scbharwal.com](http://www.drvinay@scbharwal.com)  
 DMC No. 4882

*O/E*  
*L/O ~~BR~~ last in young age P ↓*  
*CA to Spay better*  
*Chl on Per.*  
*R/O w/o Kertoplasty ok eye balls*  
*PL+*  
*PR + ~~X~~*  
*A-1*

**Dr. Malvika Sabharwal**

M.B.B.S., F.L.C.S.G., Dpt. Endo. Surgery (USA)  
 Awarded Padmaashri by the President of India  
 Chief Dept. of Gynaec. Laparoscopic, Endoscopy Surgery  
 President, Delhi Gynaec Endoscopy Society (2018)  
 Founder Chairperson: Indian Ass. of Gynaec. Endoscopists  
 International Society of Gynaec. Laparoscopic  
 American Association Gynaec. Laparoscopic  
 Federation of Obst. & Gynaec. Societies of India  
 International College of Obst. & Gynaec.  
 E-mail: [malvika@jmh.in](mailto:malvika@jmh.in)  
 Website: [www.dr.malvikasabharwal.com](http://www.dr.malvikasabharwal.com)  
 DMC No. 4888

**Deptt. of E.N.T.**

**Dr. R.K. Trivedi**

M.B.B.S., D.L.O., M.E. (ENT)  
 Senior Consultant  
 D.M.C. No. 12547

*R/O Cornua nazary*

*Eco-Tears HA Eye drops*  
*I Quilfy 100*

**Dr. Rajeev Nangia**

M.B.B.S., M.S. (ENT)  
 Senior Endoscopic Surgeon  
 DMC No. 4001

**Deptt. of Ophthalmology**

**Dr. Ashwani Seth**

M.B.B.S., M.E.  
 Senior Consultant Eye Surgeon  
 D.M.C. No. 19709

**Dr. S.C. Pahwa**

M.B.B.S., M.S. (Ophth)  
 Eye Surgeon  
 D.M.C. No. 1024

*DR. S.C. PAHWA*  
*M.B.B.S., M.S. (Ophth)*  
*EYE Specialist*  
*DMC No. - 8424*  
*Jeewan Mala Hospital*  
*New Delhi-110006*

**Deptt. of Dentistry**

**Dr. Varun Aggarwal**

B.D.S., M.D.S., CPC, M.D.A.  
 Consultant: Endodontist  
 & Oral Health

**Dr. Neha Gupta**

B.D.S., PGCHM, F.I.C.D., M.D.A.  
 Senior Consultant  
 Deptt. of Dentistry

Treatment Adv for \_\_\_\_\_ days. Next follow up visit on \_\_\_\_\_





**OPD ASSESSMENT FORM**  
(Gyn. & Obs.)

**GYNAE DEPTT.**  
 9212150582  
 9212150586  
 For Appt. 9212526855  
 Time 8 AM to 8 PM

Name of Patient: Ms. Rekha Age/Sex: (37/F) Date/Time: 15/11/24

Name of Doctor: Gynaecologist

Presenting complaints: for routine health up.

It is visually impaired

History of presenting complaints:

Menstrual History: LMP: → 3/11/24 M/H: 3/25-26 d/s.  
 EDD:

Marital History: MF x 7 yrs  
 Obstetric History: 1 2 1/2 - 1st chd f+LSU-6yrs (fetus Hosp)  
2nd chd f+LSU-3yrs (air)  
3rd chd


Past history / surgical procedures:

H/O of ? Ovarian Cancer in Mother  
(Endometrial, ? cervical)  
survived; taken Chemot RT.

A. General Physical Examination: Pallor ..... Icterus ..... Cyanosis ..... Clubbing .....

Pedal edema ..... Lymph nodes ..... Breast ..... B.P. ..... Pulse ..... Weight .....

Location: 1. P/A soft - pt is very uncooperative.  
 2. P/S Cx - pain point os  
 3. P/V Est-MS, B/V.  
MS to ...  
fecal smear taken  
fecal smear taken

Investigation	Treatment
<p>15/11/24 (JMH)</p> <p>Liver @ grade 2</p> <p>fatty liver,</p> <p>liver nb @</p> <p>Uter @ nb @</p> <p>ET: - 6.3mm</p> <p>both ovaries @;</p> <p>Glc. Advice - clerc</p>	<p>Adv</p> <p>T. CCM-1 Lab 02</p> <p>T. Upru P<sub>3</sub> - 1 lab weekly x 12 wks.</p> <p>fu &amp; report</p> 

Diet

Normal

Soft

Liquid

Other

Signature & Name of the Doctor



Mrs. Rekha  
Date: November 15, 2024

Age: 37 Y/ Sex: F  
MR No:- 37239

### ULTRASOUND WHOLE ABDOMEN

Liver is normal in size and shows diffuse increase in echogenicity s/o grade-I fatty infiltration.  
Intrahepatic bile ducts and portal radicals are normal in caliber.  
Portal vein is normal in caliber

Gall bladder does not show any evidence of cholecystitis or cholelithiasis.

- Calculus - Absent
- Sludge - Absent
- Wall edema:- Absent.
- Wall thickness:- Normal
- Pericholecystic adhesions:- Absent
- CBD- proximal visualized part. - is not dilated.
- CBD- Mid and distal segment is obscured due to technical limitation.
- Central IHBR:- normal in caliber.

Both kidneys are of normal size, shape and echopattern. No calculus, growth or hydronephrotic changes seen in either kidney. The parenchymal thickness is normal & cortico-medullary differentiation is well maintained.

Spleen is normal in size and echotexture.  
Pancreas does not show any pathology.

Urinary bladder is distended and shows no mural or intraluminal pathology.  
Uterus is anteverted and higher up in pelvis, normal in size, shape and echopattern.  
Endometrium echo is 6.3 mm  
Both the ovaries appear normal in size, shape, and echopattern.  
Bilateral adnexae are clear. No adnexal mass.  
No free fluid or pelvic collection seen.

*Please correlate clinically.*

*Ugdes*

**DR. GLOSSY B SABHARWAL, MD**  
**CONSULTANT RADIOLOGIST**

(This report is only a professional opinion and it is not valid for medico-legal purposes.)

**JEEWAN MALA HOSPITAL PVT. LTD.**

37/1, New Rohtak Road, New Delhi-110 005 (India) Tel. : 47774141-3321256/955

E-mail: info@jmh.in Website: www.jmh.in

OSTIN No. 07AABCJ0926A1ZD / CIN No. U74899DL1991PTC043833





**Patient Name :** MRS. REKHA GOYAL

**Age / Gender :** 37 years / Female

**MR No. / IPD No. :** /

**Patient Type / Bed No. :** /

**Referred By :** ARCOFEMI HEALTH CARE  
 PVT.LIMITED ( MEDIWHEEL )

**Registration Time :** Nov 15, 2024, 10:59 a.m.

**Receiving Time :** Nov 15, 2024, 10:59 a.m.

**Reporting Time :** Nov 15, 2024, 01:04 p.m.


241115068

**Panel :** Dr Arcofemi Health Care PVT.limited ( MediWheel )

**Client Code :** ACROFEMI HEALTH CARE PVT.  
 LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

### HAEMATOLOGY

#### **Complete Haemogram - Hb RBC count and indices, TLC, DLC, PLATELET, ESR.**

Hemoglobin (Hb) Method : Whole Blood, SLS-haemoglobin	12.4	g/dL	12.0 - 15.0
Erythrocyte (RBC) Count Method : Whole Blood, DC detection	3.94	x 10 <sup>6</sup> /uL	3.8 - 4.8
HCT Method : Whole Blood, RBC pulse height detection	38.7	%	36 - 46
Mean Cell Volume (MCV) Method : Whole Blood, Electrical Impedence	98.2	fL	83 - 101
Mean Cell Haemoglobin (MCH) Method : Whole Blood, Calculated	31.5	pg	27 - 32
Mean Corpuscular Hb Conc. (MCHC) Method : Whole Blood, Calculated	32.0	g/dL	32.0 - 35.0
Red Cell Distribution Width (RDW) CV Method : Whole Blood, Calculated	<b>14.1</b>	%	11.6 - 14.0
Total Leucocytes (WBC) Count Method : Whole Blood, Flow cytometry	6.3	x 10 <sup>3</sup> /uL	4 - 10
<b>DLC (Differential Leucocytes Count)</b>			
Neutrophils Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy	51.9	%	40 - 80
Lymphocytes Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy	37.8	%	20 - 40
Monocytes Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy	5.1	%	2 - 10
Eosinophils Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy	4.9	%	1 - 6
Basophils Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy	0.3	%	0 - 2
Absolute Neutrophil Count Method : Whole Blood, Calculated	3.27	x 10 <sup>3</sup> /uL	2.0 - 7.0
Absolute Lymphocyte Count Method : Whole Blood, Calculated	2.38	x 10 <sup>3</sup> /uL	1 - 3

**Patient Name :** MRS. REKHA GOYAL

**Age / Gender :** 37 years / Female

**MR No. / IPD No. :** /

**Patient Type / Bed No. :** /

**Referred By :** ARCOFEMI HEALTH CARE  
 PVT.LIMITED ( MEDIWHEEL )

**Registration Time :** Nov 15, 2024, 10:59 a.m.

**Receiving Time :** Nov 15, 2024, 10:59 a.m.

**Reporting Time :** Nov 15, 2024, 01:04 p.m.


241115068

**Panel :** Dr Arcofemi Health Care PVT.limited ( MediWheel )

**Client Code :** ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
Absolute Monocyte Count Method : Whole Blood, Calculated	0.32	x 10 <sup>3</sup> /uL	0.2-1.0
Absolute Eosinophil Count Method : Whole Blood, Calculated	0.31	x 10 <sup>3</sup> /uL	0.02 - 0.5
Absolute Basophils Count Method : Whole Blood, Calculated	<b>0.02</b>	x 10 <sup>3</sup> /uL	0.02 - 0.1
Platelet Count Method : Whole Blood, DC Detection	<b>120</b>	x 10 <sup>3</sup> /uL	150 - 410
ESR - Erythrocyte Sedimentation Rate Method : Whole blood , Modified Westergren Method	<b>22</b>	mm/hr	<20

**Interpretation:**

It indicates presence and intensity of an inflammatory process. It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, acute rheumatic fever,. It is also increased in multiple myeloma, hypothyroidism.

Tests done on Automated Six Part Cell Counter.

\*\*END OF REPORT\*\*



Dr. Arti Tripathi  
 MD Pathology  
 Chief Consultant, Pathology  
 DMC No: 43012

<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**IMMUNOLOGY**

**T3, T4, TSH ( Thyroid Profile Total),Serum**

<b>(Triiodothyronine) T3-Total</b> Method : ECLIA	0.8	ng/mL	0.80 - 2.00
<b>(Thyroxine) T4-Total</b> Method : ECLIA	5.81	ug/dL	5.10 - 14.10
<b>TSH-Ultrasensitive</b> Method : ECLIA	1.51	uIU/mL	0.27-4.20

**Interpretation**

The Biological reference interval provided is for Adults.  
 For age specific reference interval, please refer to the table given below.

TSH	T3/F13	T4/F14	Interpretation
High	Normal	Normal	Subclinical Hypothyroidism
Low	Normal	Normal	Subclinical Hyperthyroidism
High	High	High	Secondary Hypothyroidism
Low	High/Normal	High/Normal	Hyperthyroidism
Low	Low	Low	Non Thyroidal Illness/Secondary Hyperthyroidism

TSH (mU/mL)			
Children	New Born	0.7	15.2
	6 days - 3 Months	0.72	11
	4 -12 Months	0.73	8.35
	1-6 Years	0.7	5.97
	7-11 Years	0.6	4.84
	12-20 years	0.51	4.3
Adults		0.27	4.20

TSH levels are subjected to circadian variation, rising several hours before the onset of sleep, reaching peak levels between 11 pm and 6 am. Nadir concentration are observed during the afternoon. diurnal variation in TSH levels is approx 50%+/-, hence time of the day can influence the measured serum concentration.

\*\*END OF REPORT\*\*

<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------



Dr. Arti Tripathi  
MD Pathology  
Chief Consultant, Pathology  
DMC No: 43012



<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**HAEMATOLOGY**

**Blood Group (ABO)**

Blood Group	"A"		
Method : Forward and Reverse by Slide method			
RH Factor	Positive		

**Methodology**

This is done by forward and reverse grouping by slide agglutination method.

**Interpretation**

Newborn baby does not produce ABO antibodies until 3 to 6 months of age. So the blood group of the Newborn baby is done by ABO antigen grouping (forward grouping) only, antibody grouping (reverse grouping) is not required. Confirmation of the New-born's blood group is indicated when the A and B antigen expression and the isoagglutinins are fully developed (2-4 years).

\*\*END OF REPORT\*\*



Dr. Arti Tripathi  
MD Pathology  
Chief Consultant, Pathology  
DMC No: 43012

<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**BIOCHEMISTRY**

**LFT (Liver Function Test,Serum)**

<b>Total Protein</b> Method : Biuret Method	7.8	g/dL	6.4-8.3
<b>Albumin</b> Method : Bromocresol Green	4.5	g/dL	3.5 - 5.2
<b>Globulin</b> Method : Calculated	3.30	g/dL	1.8 - 3.6
<b>A/G Ratio</b> Method : Calculated	1.36	ratio	1.2 - 2.2
<b>SGOT</b> Method : IFCC without Pyridoxal Phosphate	24	U/L	0 to 32
<b>SGPT</b> Method : IFCC without Pyridoxal Phosphate	21	U/L	0 to 33
<b>Alkaline Phosphatase-ALP</b> Method : PNP AMP Kinetic	88	U/L	35-104
<b>GGT-Gamma Glutamyl Transferase</b> Method : IFCC	10	U/L	0 to 40
<b>Bilirubin Total</b> Method : Colorimetric Diazo Method	0.50	mg/dL	0.0-0.90
<b>Bilirubin - Direct</b> Method : Colorimetric Diazo Method	0.10	mg/dL	Adults and Children: < 0.30
<b>Bilirubin - Indirect</b> Method : Calculated	0.40	mg/dL	0.1 - 1.0

**Interpretation :**

**SGOT/ SGPT:** Increased in Acute viral hepatitis, Biliary tract obstruction (cholangitis, choledocholithiasis), Alcoholic hepatitis and Cirrhosis, liver abscess, metastatic or primary liver cancer; non-alcoholic steatohepatitis; right heart failure. Decreased in Pyridoxine (vit B6) deficiency.

**Alkaline Phosphatase:** Increased in Obstructive hepatobiliary disease, Bone disease (physiologic bone growth, Paget disease, Osteomalacia, Osteogenic sarcoma, Bone metastases), Hyperparathyroidism, Rickets, Pregnancy (third trimester). Decreased in Hypophosphatasia.

**GGT:** Increased in Liver disease Acute viral or toxic hepatitis, Chronic or subacute hepatitis, Alcoholic hepatitis, Cirrhosis, Biliary tract obstruction.

**Protein:** Moderate-to-marked hyperproteinemia maybe due to multiple myeloma and other malignant paraproteinemias, Hypoproteinemia may be due to decreased production or increased protein loss.

**Albumin:** Increased in Dehydration, Shock, Hemoconcentration. Decreased in hepatic synthesis(Chronic liver disease, malnutrition, malabsorption, malignancy), Increased losses (Nephrotic syndrome, Burns, Trauma, Hemorrhage with fluid replacement, acute or chronic glomerulonephritis), Hemodilution (pregnancy, CHF) and Drugs (estrogens).

**Bilirubin:** A substance produced during the normal breakdown of red blood cells.Elevated levels of bilirubin (jaundice) might indicate liver damage or disease or certain types of anemia.

<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

\*\*END OF REPORT\*\*



Dr. Anil Tripathi  
MD Pathology  
Chief Consultant, Pathology  
DMC No: 43012

<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**BIOCHEMISTRY**

**KFT (Renal Function Test,Serum)**

<b>Urea</b> Method : kinetic (urease-GLDH)	21.4	mg/dL	16.6-48.5
<b>BUN</b> Method : Calculated	10.00	mg/dL	6-20
<b>Creatinine</b> Method : Kinetic Colorimetric (Jaffe Method)	0.70	mg/dL	0.30-1.10
<b>Uric Acid</b> Method : Enzymatic Colorimetric: Uricase-POD	4.6	mg/dL	2.4-5.7

**Interpretation :**

**Urea:-** Increased in renal diseases,urinary obstructions, shock, congestive heart failure .Decreased in liver failure and pregnancy.

**Creatinine :-** Elevated in renal dysfunction, reduced renal blood flow shock, dehydration, Congestive heart failure, Diabetes Acromegaly. Decreased levels are found in Muscular Dystrophy.

**Uric acid:-** Increased in Gout, Arthritis, impaired renal functions and starvation.Decreased in Wilson's disease, Fanconis Syndrome and Yellow Atrophy of Liver.

**Sodium:-**Increased in Excessive dietary salt ,Diuretic therapy,Adrenal insufficiency,Salt-wasting nephropathy and Vomiting.Decreased levels are seen in Hyperaldsteronism ,Hyponatremia,Prerenal Azotemia,Renal Failure and Glomerulonephritis.

**Potassium:-** Low levels is common in vomiting, diarrhea, alcoholism, and folic acid deficiency. Increase level are seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid potassium infusion.

**Chloride:-** Increased in dehydration, renal tubular acidosis, acute renal failure, metabolic acidosis, diabetes insipidus, adrenocortical hyperfuction. Decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis.

\*\*END OF REPORT\*\*



Dr. Arti Tripathi  
MD Pathology  
Chief Consultant, Pathology  
DMC No: 43012



<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
<b>BIOCHEMISTRY</b>			
<b>Lipid Profile,Serum</b>			
<b>Cholesterol-Total</b> Method : Enzymatic Colorimetric,CHOD-POD	195	mg/dL	Desirable: <= 200 Borderline High: 201-239 High: > 239 Ref: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.■■■■■■■■■
<b>Triglycerides</b> Method : Enzymatic Colorimetric ,GOD-POD	184	mg/dL	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500
<b>Cholesterol-HDL Direct</b> Method : CHOD-POD (Homogenous Enzymatic)	47	mg/dL	No Risk - >65 mg/dL Moderate risk - 45-65 mg/dL High risk - < 45 mg/dL
<b>LDL Cholesterol</b> Method : Calculated	111.20	mg/dL	Optimal: < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very High: >= 190
<b>Non - HDL Cholesterol, Serum</b> Method : Calculated	148	mg/dL	Desirable: < 130 mg/dL Borderline High: 130-159mg/dL High: 160-189 mg/dL Very High: > or = 190 mg/dL
<b>VLDL Cholesterol</b> Method : Serum, Calculated	36.80	mg/dL	0 - 30
<b>CHOL/HDL RATIO</b> Method : Calculated	4.15	Ratio	3.5 - 5.0
<b>LDL/HDL RATIO</b> Method : Calculated	2.37	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0
<b>HDL/LDL RATIO</b> Method : Calculated	0.42	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0

**Note:** 10-12 hours fasting sample is required.

<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

\*\*END OF REPORT\*\*



Dr. Arti Tripathi  
MD Pathology  
Chief Consultant, Pathology  
DMC No: 43012

<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068F <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	---

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**BIOCHEMISTRY**

<b>Glucose ( Fasting)</b> <b>Glucose Fasting</b> Method : Plasma,Enzymatic Hexokinase	107	mg/dL	Normal: 72-106 Impaired Tolerance: 100-125 Diabetes mellitus: $\geq 126$ (on more than one occasion) (American diabetes association guidelines 2018)
---	-----	-------	--

**Interpretation**

Glucose is the major carbohydrate present in the peripheral blood. Oxidation of glucose is the major source of cellular energy in the body. The concentration of glucose in blood is controlled within the narrow limits by many hormones, the most important of which are produced by the pancreas. The most frequent cause of hyperglycaemia is diabetes mellitus resulting from deficiency in insulin secretion or action. These include pancreatitis, thyroid dysfunction, renal failure, and liver disease. Hypoglycaemia is less frequently observed. A variety of conditions may cause low blood glucose levels such as insulinoma, hypopituitarism, or insulin induced hypoglycaemia.

\*\*END OF REPORT\*\*



Dr. Arti Tripathi  
MD Pathology  
Chief Consultant, Pathology  
DMC No: 43012

<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 03:46 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

**BIOCHEMISTRY**

**Glycated Hb (HbA1c)**

<b>HbA1c (Glycated Hemoglobin)</b>	5.3	%	Non-Diabetic : <5.7
Method : EDTA Whole blood, HPLC, NGSP certified			Pre Diabetes : 5.7 - 6.4
			Diabetes : ≥ 6.5

**Estimated Average Glucose :** 105.41 mg/dL

**Interpretations**

- HbA1c has been used as one of the key biomarkers in identifying patients with Diabetes . American Diabetes Association (ADA) and several clinical groups have endorsed utility of HbA1c testing using a cut off value of 6.5%. The average concentration of blood glucose(eBG) is reflected in this test over a period of the past three months.
- Therapeutic goals for monitoring Diabetes.
  - Goal of therapy < 7% HbA1c.
  - Action suggested > 8 % HbA1c
- Patients with shortened red cell survival( hemolytic disease), recent significant blood loss have lower HbA1c values .
- High HbA1c is associated with Iron deficiency ,patients with polycythemia or post splenectomy.

**Note :** The presence of hemoglobin variants can interfere with measurement of HbA1c.

\*\*END OF REPORT\*\*



Dr. Arti Tripathi  
MD Pathology  
Chief Consultant, Pathology  
DMC No: 43012



<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

### CLINICAL PATHOLOGY

#### Urine (RE/ME)

##### Physical Examination :

Volume Method : Visual Observation	40		mL
Colour Method : Visual Observation	Pale Yellow		Pale Yellow
Transparency (Appearance) Method : Visual Observation	Clear		Clear
Deposit Method : Visual Observation	Absent		Absent
Reaction (pH) Method : Double Indicator method	6.0		4.5 - 8.0
Specific Gravity Method : Ionic Concentration	1.015		1.010 - 1.030

##### Chemical Examination (Dipstick Method) Urine

Urine Protein Method : Protein Ionisation/ Manual	Absent		Absent
Urine Glucose (sugar) Method : Oxidase Reaction/ Manual	Absent		Absent
Blood (Urine) Method : Peroxidase Reaction	Absent		Absent

##### Microscopic Examination Urine

Pus Cells (WBCs) Method : Microscopy	1 - 2	/hpf	0 - 5
Epithelial Cells Method : Microscopy	1 - 2	/hpf	0 - 4
Red blood Cells Method : Microscopy	Absent	/hpf	Absent
Crystals Method : Microscopy	Absent		Absent
Cast Method : Microscopy	Absent		Absent
Yeast Cells Method : Microscopy	Absent		Absent
Amorphous Material Method : Microscopy	Absent		Absent

<b>Patient Name :</b> MRS. REKHA GOYAL <b>Age / Gender :</b> 37 years / Female <b>MR No. / IPD No. :</b> / <b>Patient Type / Bed No. :</b> / <b>Referred By :</b> ARCOFEMI HEALTH CARE PVT.LIMITED ( MEDIWHEEL )		<b>Registration Time :</b> Nov 15, 2024, 10:59 a.m. <b>Receiving Time :</b> Nov 15, 2024, 10:59 a.m. <b>Reporting Time :</b> Nov 15, 2024, 12:47 p.m.  241115068 <b>Panel :</b> Dr Arcofemi Health Care PVT.limited ( MediWheel ) <b>Client Code :</b> ACROFEMI HEALTH CARE PVT. LTD. (MEDIWHEEL)
--	---	--

Test Description	Value(s)	Unit(s)	Reference Range
Bacteria	Absent		Absent
Method : Microscopy			
Others	Absent		

Remarks:-

Epithelial cells	Urolithiasis bladder carcinoma or hydronephrosis ,ureteric stents or bladdercatheters for prolonged periods of time.
Granular casts	Low intratubular pH,high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration,acute congestive heart failure, renal diseases.
Calcium Oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of VitaminC, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit( A verrhoa carambola)or its juice
Uric acid	Artharitis
Bacteria	Urinary infection when present in significant numbers and with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

\*\*END OF REPORT\*\*



Dr. Arti Tripathi  
 MD Pathology  
 Chief Consultant, Pathology  
 DMC No: 43012